FDA
-
-
-
-
-
-
-
Deciphera Pharmaceuticals Announces Positive Top-line Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) and Updated Results from Phase 1/2
-
-
-
-
-
-
-
Deciphera Pharmaceuticals Announces Planned 2023 Corporate Milestones to Support Continued Evolution to Multi-Product Company
-
-
-
-
-
-
-
Deciphera Pharmaceuticals (DCPH) Presents Preclinical Data from DCC-3116 Program at the AACR Annual Meeting
-
-
-
-
-
-
-
Deciphera Pharmaceuticals (DCPH) Receives European Commission Approval of QINLOCK for tTreatment of Fourth-Line Gastrointestinal Stromal Tumor
-
-
-
-
-
-
-
Deciphera Announces Approval of QINLOCK® in Switzerland for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
-
-
-
-
-
-
-
Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2021 Financial Results
-
-
-
-
-
-
-
Deciphera Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 4, 2021
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

